Sleep Disturbances in Progressive Supranuclear Palsy: Evaluation and Management
For patients with PSP experiencing sleep disturbances, prioritize evaluation with video-polysomnography to characterize the specific sleep architecture disruption, then consider trial of suvorexant (orexin antagonist) over traditional GABAergic hypnotics based on the unique pathophysiology of wake-promoting nuclei preservation in PSP.
Understanding the Sleep Pathophysiology in PSP
Sleep dysfunction in PSP is profound and mechanistically distinct from other neurodegenerative disorders. The disease preferentially affects sleep-promoting nuclei (dorsal raphe nucleus, locus coeruleus, pedunculopontine nucleus) while relatively sparing wake-promoting orexinergic neurons in the lateral hypothalamus 1. This creates a pathological imbalance—essentially "hyperinsomnia" or inability to generate adequate sleep despite preserved wake drive.
Key polysomnographic findings consistently demonstrate 2, 3:
- Severe reduction in total sleep time (often <5 hours/night)
- Decreased N2, N3, and REM sleep stages
- Increased wake after sleep onset (WASO)
- Prolonged sleep latencies
- Fragmented sleep architecture with frequent awakenings
- 24-hour sleep deprivation despite daytime naps (which are typically <60 minutes and consist mainly of light sleep) 4
Clinical Evaluation Algorithm
Step 1: Characterize Sleep Complaints
Look specifically for:
- Insomnia severity (more pronounced than in Parkinson's disease) 3
- Nocturnal awakenings and inability to maintain sleep
- Daytime naps that are brief and non-restorative
- Probable RBD symptoms (present in 18.7% of PSP patients) 5
- Periodic limb movements (common, though not significantly more than PD) 3
- Restless leg syndrome, agrypnia excitata 6
Critical pitfall: Only a minority of PSP patients report excessive daytime sleepiness despite severe objective sleep deprivation 4, so absence of this complaint does not exclude significant sleep dysfunction.
Step 2: Objective Sleep Assessment
Video-polysomnography is the gold standard for PSP sleep evaluation 2. This reveals:
- Quantification of sleep stage reductions
- Detection of REM sleep without atonia (found in some patients)
- Assessment of periodic limb movements
- Evaluation of sleep-related breathing disorders
Home-based polysomnography is feasible and reduces patient burden 3.
Step 3: Assess Associated Features
Sleep disturbances correlate with:
- Greater non-motor symptom burden 5
- Poorer quality of life 5
- Attention/memory deficits and gastrointestinal symptoms (independent predictors of pRBD) 5
- Autonomic dysfunction with sympathetic predominance (elevated body core temperature, abnormal nocturnal blood pressure patterns in 86% of patients) 4
Treatment Approach
Pharmacological Management
The most promising approach targets the preserved wake-promoting system rather than the degenerated sleep-promoting system. A randomized controlled trial protocol specifically designed for PSP compares 1:
Suvorexant 15 mg/day (orexin antagonist) - Preferred first-line based on PSP pathophysiology
- Targets the relatively spared orexinergic wake-promoting neurons
- Addresses the fundamental pathophysiological imbalance in PSP
- Mechanistically superior to sleep-promoting agents
Zolpidem 5 mg/day (GABAergic agonist) - Second-line option
- Targets sleep-promoting systems that are already degenerated in PSP
- Less mechanistically rational but may provide symptomatic benefit
Avoid traditional sleep-promoting medications as monotherapy given the degeneration of sleep nuclei makes them theoretically less effective
Treatment Monitoring
Given the remote trial design feasibility 1, monitoring can include:
- Ambulatory EEG and actigraphy for objective sleep/circadian assessment
- Subjective questionnaires (Pittsburgh Sleep Quality Index, Insomnia Severity Index)
- Cognitive testing to assess impact on attention/memory
Non-Pharmacological Considerations
While no specific guidelines exist for PSP, address:
- Autonomic dysfunction contributing to sleep disruption (sympathetic predominance with elevated nocturnal body temperature and blood pressure) 4
- Environmental temperature control (given elevated body core temperature during sleep)
- Management of comorbid conditions (RLS, periodic limb movements, gastrointestinal symptoms)
Critical Clinical Caveats
The sleep disruption in PSP occurs early in disease progression 2, so evaluation should not be delayed until advanced stages. The profound 24-hour sleep deprivation may worsen cognitive function and quality of life, making treatment a priority even when patients don't spontaneously report excessive sleepiness.
RBD in PSP has different implications than in synucleinopathies—it represents tauopathic rather than synucleinopathic pathology and is associated with greater overall non-motor burden 5.
The autonomic dysfunction with sympathetic predominance may be either the primary driver of sleep-wake disruption or a consequence of chronic sleep loss 4—this bidirectional relationship suggests treating both sleep and autonomic symptoms may be necessary for optimal outcomes.